Glen Clova Scientific

Glen Clova Scientific

Biotechnology Research

Developing a new generation of active biologic drugs

About us

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. #Glenclovascientific #Dundee

Website
https://glenclovascientific.com/
Industry
Biotechnology Research
Company size
2-10 employees
Type
Privately Held

Employees at Glen Clova Scientific

Updates

  • We are looking forward to the #ScotLifeSci24 tomorrow at The Technology and Innovation Centre (TIC), where Steven Powell will be joining Mark Beaumont and Dr Poonam Malik, MBA, FRSE FRSB at 3pm for a panel discussion on 'Growth & Funding' and Tips for SME's. University of Dundee #lifesciences #biotech National World Events sciences

    View organization page for Glen Clova Scientific, graphic

    475 followers

    Our CEO, Dr Steven Powell, will be discussing 'Growth & Funding' at the Scotsman Life Sciences Conference, taking place on Thursday 28 November at The Technology Innovation Centre, Glasgow. As part of a panel discussion in the field of ‘Growth and Funding’ at 3.00pm, Steven will be joined by other industry experts and will be sharing insights from his own journey with Glen Clova Scientific in Scotland’s Life Sciences industry. This year’s theme will explore the economic future for Life Sciences in Scotland, bringing together industry experts to network, learn and drive innovation and growth. Attending will be a cross section of Life Science sectors including politicians, academia, business leaders, public sector and company managers. Steven will also be discussing ‘Tips for SME’s’ in the following session at 3.45pm giving practical advice on how to take your innovation forward. These discussions will be invaluable for anyone looking to scale their business and navigate the complex landscape of funding. Please email  info@glenclovascientific.com if you would like the opportunity for a meeting with Steven. #LifeScience #Biotech

    • No alternative text description for this image
  • Our CEO, Dr Steven Powell, will be discussing 'Growth & Funding' at the Scotsman Life Sciences Conference, taking place on Thursday 28 November at The Technology Innovation Centre, Glasgow. As part of a panel discussion in the field of ‘Growth and Funding’ at 3.00pm, Steven will be joined by other industry experts and will be sharing insights from his own journey with Glen Clova Scientific in Scotland’s Life Sciences industry. This year’s theme will explore the economic future for Life Sciences in Scotland, bringing together industry experts to network, learn and drive innovation and growth. Attending will be a cross section of Life Science sectors including politicians, academia, business leaders, public sector and company managers. Steven will also be discussing ‘Tips for SME’s’ in the following session at 3.45pm giving practical advice on how to take your innovation forward. These discussions will be invaluable for anyone looking to scale their business and navigate the complex landscape of funding. Please email  info@glenclovascientific.com if you would like the opportunity for a meeting with Steven. #LifeScience #Biotech

    • No alternative text description for this image
  • We have a new opportunity for a Business Analyst (BA)!   The BA will be a key link between the GCS R&D team and business activities, translating R&D plans and strategies into commercial opportunities and ensuring effective business development processes. They will have responsibility for corporate communications and ensure all external material reflects corporate strategies. The ideal candidate will have gained industry experience in a drug development environment and have a working knowledge of the biotechnology landscape, and preferably some exposure to technology licensing activities within either a pharmaceutical or biotech company. We are looking for someone with exemplary market analytical skills, a good understanding of corporate marketing, and experience in establishing and managing CRM and market databases. Strong planning, budgeting, project management and written reporting skills are essential.   To view full details of the role, apply today: https://lnkd.in/gpjPau7H

    • No alternative text description for this image
  • We’re excited to be attending BIO-Europe 2024, taking place in Stockholm, Sweden, from 4-6 November!   As one of Europe’s premier partnering conferences in the life sciences sector, BIO-Europe brings together industry leaders, innovators, investors and experts to network and share the latest updates in life sciences.   Our CEO, Steven Powell, will be representing the company and is looking forward to connecting with fellow professionals in the life science community.   If you’d like to schedule a meeting with Steven, feel free to reach out at info@glenclovascientific.com or connect with him directly here on LinkedIn.   #BIOEurope2024 #LifeSciences

    • No alternative text description for this image
  • Join our team! We're hiring a new Senior Scientist Upstream Development.   Apply here 👉https://lnkd.in/gqtHNrmc   Based in the vibrant biotech hub of Dundee, you'll lead lab-scale upstream process development for our candidate prototype drugs expressed in E.coli. You’ll also support process development on other platforms (mammalian, Baculovirus, yeast/plant) as needed. Other responsibilities include overseeing strain development, implementing lab-scale fermentation, supervising technicians, and liaising with external providers of specialised technologies.   What we offer: 💼 £40k-£50k salary + bonus scheme 💰 Pension + stock options 🏡 Relocation support 🚗 Free on-site parking 📈 Career growth opportunities 📅 24 days holiday + Scottish public holidays   If you hold a PhD in a biomedical field and have experience in upstream process development, this could be the role for you!   Apply by 8 November 2024 or share this post with your network.

    • No alternative text description for this image
  • Our Director of Research and Development Operations, Dr Amanda M., will be attending CPHI Europe in Milan from 8-10 October!   This global event provides a fantastic opportunity to spark new collaborations with industry leaders and stay updated on the latest innovations in pharma. Amanda is excited to connect with this huge network of professionals over the three days.   If you're attending and want to learn more about our work, explore a potential collaboration, or just want to network with like-minded professionals, feel free to reach out at info@glenclovascientific.com or connect with Amanda on LinkedIn!   #CPHI

    • No alternative text description for this image
  • We are moving to new facilities in the Dundee University Incubator!   This move follows the first close of a £4 million seed funding round and will enable us to advance the development of a new generation of active biologic drugs. In our new home at the Incubator, we will refurbish and equip a suite of research and development laboratories.    Our Co-Founder, Dr John Foerster, commented, “We are delighted to be able to locate our new laboratories so closely to the University. This will enable GCS to continue to interact with University teams and facilities when required. It is also important to GCS to continue to participate the growing biotech ecosystem in both Dundee and Scotland”   Read more in The Courier: https://lnkd.in/gGmBJ8pn   #ActiveBiologicDrugs #VLPs #Biopharma

    • No alternative text description for this image
  • We’ve been featured in the summer 2024 edition of Drug Discovery World! Read the interview with our co-founder, Steven Powell, on page 62 in the Start-up Zone. Steven discusses how we are using virus-like particles (VLPs) to overcome the challenges associated with the first generation biological therapeutics in treating chronic inflammatory and autoimmune conditions like eczema and asthma, and the current market for this therapeutic area. Read it here: https://lnkd.in/gtSZijU9 

    • No alternative text description for this image
  • We are happy to share the appointment of Dr Amanda M. as our new Director of R&D. Amanda will be instrumental in driving the development of our next-generation active biologic drugs for chronic inflammatory and autoimmune disorders. She will also play an important  role in building a partner network around our proprietary GCS VLP platform. With over 10 years of experience in the UK pharma, biotech, CRO and academic sectors, she brings a wealth of knowledge to the team and her experience in advancing R&D activities in both commercial and academic settings will be invaluable. A warm welcome to the team Amanda! Find out more about us: https://lnkd.in/gVgGkB8w #VLPs #biopharma #biologics

    • No alternative text description for this image

Similar pages